Necrotizing Enterocolitis Market Positioned for Rapid Growth Through 2034, DelveInsight Finds

The Necrotizing Enterocolitis (NEC) market in the 7MM (The United States, EU4—Germany, France, Italy, and Spain, the United Kingdom, and Japan) is projected to exceed USD 700 million by 2034. DelveInsight's comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the NEC landscape.

By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The NEC market is increasingly driven by a shift from reactive treatment strategies to preventive approaches. IBP-9414, a pharma-grade probiotic under development by Infant Bacterial Therapeutics (IBT), represents a breakthrough opportunity in the market. Currently, no FDA-approved pharmaceutical treatments exist specifically for NEC, creating a significant unmet medical need and positioning the first approved therapy to capture substantial market share.

DelveInsight's report, "Necrotizing Enterocolitis Market Insights, Epidemiology, and Market Forecast-2034," provides a comprehensive analysis of the Necrotizing Enterocolitis (NEC) landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines NEC market dynamics, offering a thorough assessment of current and emerging market trends, prevention patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Necrotizing Enterocolitis market outlook, drug uptake, treatment scenario and epidemiology trends, visit Necrotizing Enterocolitis Market Forecast 

Some of the key facts of the Necrotizing Enterocolitis Market Report:

• Key Necrotizing Enterocolitis Companies: Infant Bacterial Therapeutics, Infinant Health, and others
• Key Necrotizing Enterocolitis Therapies: IBP-9414 (Lactobacillus reuteri), INF108, early exposure to colostrum and mother's milk, probiotics, environmental protection, and skin-to-skin care (SSC)
• The Necrotizing Enterocolitis market is expected to surge due to the disease's high mortality burden, lack of effective pharmaceutical treatments, and increasing focus on preventive strategies during the forecast period. Furthermore, launching pharma-grade probiotic therapies will significantly revolutionize the Necrotizing Enterocolitis market dynamics and patient outcomes.

Necrotizing Enterocolitis Overview

Necrotizing Enterocolitis (NEC) is a life-threatening illness almost exclusively affecting neonates, particularly premature infants. The pathophysiology of NEC involves inflammation of the intestine leading to bacterial invasion, causing cellular damage and death, which results in necrosis of the colon and intestine. As NEC progresses, it can lead to intestinal perforation, causing peritonitis, sepsis, and death. NEC is caused by bacterial invasion into the intestinal wall, leading to inflammation and cellular destruction. If unrecognized and untreated, intestinal perforation may occur, causing spillage of intestinal contents into the peritoneum and resulting in peritonitis. In premature neonates, gastrointestinal tract immaturity plays a significant role in the pathogenesis of NEC. The signs and symptoms of NEC—poor feeding, vomiting, lethargy, and abdominal tenderness—are nonspecific, requiring clinicians to maintain high clinical suspicion when presented with these signs in the neonatal population.

Key Trends in Necrotizing Enterocolitis Treatment and Prevention Landscape:

• Rising Adoption of Probiotic-Based Prevention: Increasing use of probiotics and pharma-grade probiotic drugs to prevent NEC in very low birth weight infants (VLBWI)
• Shift from Reactive to Preventive Strategies: Enhanced focus on prevention through early exposure to colostrum and mother's milk, nutritional optimization, and probiotics
• Pharma-Grade Product Development: Development of FDA-regulated pharmaceutical-grade probiotics to replace current dietary supplement-level products with uncertain safety profiles
• Neonatal Care Standardization: Adoption of skin-to-skin care (SSC), environmental protection measures, and standardized feeding protocols to reduce NEC incidence
• Infrastructure and Accessibility Improvements: Expansion of neonatal intensive care (NICU) capabilities and enhanced access to preventive therapies across the 7MM
• International Variation in Prevention Practices: Differential adoption rates of probiotics across geographies, with Europe and Asian countries leading the United States

Necrotizing Enterocolitis Epidemiology

The report on Necrotizing Enterocolitis (NEC) epidemiology provides a comprehensive analysis of the disease's prevalence, incidence, and patient demographics. It includes data on preterm infants by birth weight, regional and global trends, and projections for future epidemiological trends. The report highlights disease burden, risk factors associated with gestational age and birth weight, and mortality patterns, helping stakeholders understand the scope of NEC and plan targeted interventions, research, and prevention strategies.

In 2023, the United States had the highest total number of incident cases of preterm infants with a birth weight (≤1,500 g) among the 7MM. As per estimates, the incident cases of preterm infants by birth weight (≤1,500 g) in the 7MM are anticipated to increase during the forecast period of 2024–2034. The total number of incident cases of Necrotizing Enterocolitis in the US was approximately 4,000 cases in 2023 and is expected to decline during the forecast period due to improved preventive measures and increased adoption of probiotic therapies.

Necrotizing Enterocolitis Epidemiology Segmentation:

The Necrotizing Enterocolitis market report provides epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total incident cases of preterm infants by birth weight (≤1,500 g)
• Total incident cases of Necrotizing Enterocolitis

Download the report to understand which factors are driving Necrotizing Enterocolitis epidemiology trends @ Necrotizing Enterocolitis Epidemiology Forecast

Recent Developments in the NEC Treatment and Prevention Landscape:

• In May 2025, Infinant Health announced that the FDA has granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) to its investigational drug candidate, INF108, for the prevention of Necrotizing Enterocolitis in preterm infants, highlighting regulatory recognition of unmet medical needs in this vulnerable population.

Necrotizing Enterocolitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of potential drugs expected to be launched in the Necrotizing Enterocolitis market during the study period. The analysis covers NEC market uptake by drugs and patient uptake by therapies. Currently, there are no FDA-approved pharmaceutical therapies for Necrotizing Enterocolitis, representing a significant market gap. IBP-9414 stands as the primary medication in advanced development aimed at reducing or preventing the incidence of NEC in premature babies (≤1,500 grams).

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind maximal use. The report also covers the Necrotizing Enterocolitis Pipeline Development Activities, providing valuable insights about different therapeutic candidates in various stages and the key companies involved in developing preventive therapeutics.

Necrotizing Enterocolitis Therapies and Key Companies

• IBP-9414 (Lactobacillus reuteri): Infant Bacterial Therapeutics
• INF108: Infinant Health

To know more about Necrotizing Enterocolitis companies working in the treatment and prevention market, visit @ Necrotizing Enterocolitis Clinical Trials and Therapeutic Assessment 

Necrotizing Enterocolitis Market Drivers

• High mortality burden of NEC in neonates requiring innovative preventive and therapeutic approaches
• Complete absence of FDA-approved pharmaceutical treatments, creating urgent unmet medical needs
• Increasing prevalence of premature births globally, expanding the at-risk patient population
• Growing recognition of probiotic efficacy in preventing NEC, supported by meta-analyses and clinical evidence
• Rising healthcare expenditure on neonatal intensive care and support for rare pediatric disease therapies
• Development of pharma-grade probiotic therapies offering improved safety and efficacy profiles compared to dietary supplements
• Enhanced awareness among healthcare professionals regarding preventive strategies for NEC

Necrotizing Enterocolitis Market Barriers

• Absence of FDA-approved products limiting clinical adoption despite strong clinical evidence for probiotics
• Contamination and safety concerns associated with current dietary supplement-level probiotic products
• Lack of clear, standardized guidelines regarding which probiotic to use and patient selection criteria
• Limited clinical evidence and regulatory pathways for probiotic-based therapies
• High cost considerations for implementing pharmaceutical-grade therapies in resource-limited settings
• Variable reimbursement policies across geographies affecting patient access to preventive therapies
• Long-term safety concerns regarding permanent microbiome alterations from probiotic administration in vulnerable populations
• Limited awareness and adoption in certain regions despite strong clinical rationale

Scope of the Necrotizing Enterocolitis Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Necrotizing Enterocolitis Companies: Infant Bacterial Therapeutics, Infinant Health, and others
• Key Necrotizing Enterocolitis Therapies: IBP-9414, INF108, preventive strategies including probiotics, early colostrum exposure, skin-to-skin care, and environmental protection
• Necrotizing Enterocolitis Therapeutic Assessment: Current prevention practices and Necrotizing Enterocolitis emerging therapies
• Necrotizing Enterocolitis Market Dynamics: Necrotizing Enterocolitis market drivers and Necrotizing Enterocolitis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Necrotizing Enterocolitis Unmet Needs, KOL's views, Analyst's views, Necrotizing Enterocolitis Market Access and Reimbursement

Discover more about therapies set to grab major Necrotizing Enterocolitis market share @ Necrotizing Enterocolitis Treatment Market